Previous 10 | Next 10 |
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with this event. For further details see: Ziopharm Oncology (ZIOP) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow
At J.P. Morgan Healthcare Conference, Ziopharm Oncology ([[ZIOP]] +12.3%) said that cash/equivalents of $135.5M as of 30 September would be sufficient to fund planned operations and execute strategy into mid-2022.Upcoming Milestones:On track for FDA sign-off for Phase 1/2 IND for Library TCR-...
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziophar...
BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C....
The regulatory authority in Taiwan has signed off investigational new drug application from Eden BioCell, a 50-50 joint venture between Ziopharm Oncology (ZIOP) its partner TriArm Therapeutics, for Phase 1 trial to evaluate patient-derived CD19-specific CAR-T, in patients with relap...
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after ge...
Ziopharm Oncology ([[ZIOP]] +1.6%) reports the election of Jaime Vieser and Holger Weis to its board of directors in a consent solicitation initiated by WaterMill Asset Management.Chairman Scott Tarriff is stepping down from the board, effective immediatelyIn October, Ziopharm said WaterMill ...
Highlights That Holders of More Than 50% of Ziopharm’s Outstanding Shares Consented to Adding Each of WaterMill’s Director Candidates Thanks Shareholders for Significant Support and Reaffirms Commitment to Always Doing What is Best for Ziopharm ...
BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Manag...
Ziopharm Oncology (ZIOP) announced that Satyavrat (Sath) Shukla, CFA, CFO, has informed the company of his intention to step down from the role effective Dec. 31, 2020 to pursue another opportunity.The company has initiated a search for a new CFO. For further details see: Ziopharm Oncol...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...